The Obesity Pill Market Shift: A Global Opportunity Beckons Bank of America's recent price target increase for Eli Lilly (LLY) stock has drawn attention to an often overlooked aspect of the company's business: its growing presence in international obesity markets.
For years, the US has dominated Lilly's sales, but a new trend is emerging that could potentially outsize domestic revenues.
The global growth of GLP 1 drugs, used to treat both diabetes and obesity by curbing appetite, is driving this shift.